Home
Search
SurgiMabSurgiMab
  • Tumor detection
  • Clinical development
  • Company
    • Team
    • Partners
    • Investors
  • News & Events
  • Contact us
  • Français
SurgiMab announces SGM-101 publication in Surgical Oncology
  • Tumor detection
  • Clinical development
  • Company
    • Team
    • Partners
    • Investors
  • News & Events
  • Contact us
  • Français
EnglishEnglishFrançaisFrançais

SurgiMab announces SGM-101 publication in Surgical Oncology

SurgiMab > News & Events > News > SurgiMab announces SGM-101 publication in Surgical Oncology
Surgical Oncology
29 March 2017 Administrateur SurgiMab0

SurgiMab is happy to announce the publication of its manuscript entitled “SGM-101: An innovative near-infrared dye-antibody conjugate that targets CEA for fluorescence-guided surgery” in the peer-reviewed journal Surgical Oncology. This paper describes the Near-Infrared fluorescent CEA-targeting molecule developped by SurgiMab as well as pre-clinical tumor-targeting results in murine tumor models.

Please click on the following link to get a pdf version of the article. Surg Oncol 26 153 Gutowski M Framery B

Previous Post
SurgiMab will attend the World Molecular Imaging Congress 2016 in New York, september 7-10.
Next Post
SurgiMab is an Entrepreneur Sponsor of the first Boston-Paris Biotechnology Summit

Recent Posts

  • SurgiMab co-sponsors the Molecular-Guided Surgery meeting that will take place during the SPIE Photonics West conference in San Francisco on Jan 22-23, 2022.
  • SurgiMab will attend the 7th Annual International Congress for Fluorescence-Guided Surgery – Coral Gables, FL, 15th and 16th feb. 2020.
  • SurgiMab sponsors the conference “Molecular-Guided Surgery” of the SPIE Photonics West meeting – San Francisco, 1st and 2nd feb. 2020.
  • SurgiMab announces recruitment of first US patient in pivotal Phase 3 clinical trial evaluating SGM-101 in colorectal cancer patients
  • SurgiMab advances SGM-101 into pivotal Phase 3 clinical trial to improve surgical outcomes in colorectal cancer patients
SurgiMab
Tumor detection Clinical development Company News & Events Contact

About SurgiMab

SurgiMAb develops injectable fluorescent conjugates to be used during Fluorescence-Guided Surgery (FGS) by oncology surgeons so they can clearly delineate tumors and visualize infra-clinical size nodules invisible to their naked eyes.

Latest news

  • SurgiMab co-sponsors the Molecular-Guided Surgery meeting that will take place during the SPIE Photonics West conference in San Francisco on Jan 22-23, 2022.
  • SurgiMab will attend the 7th Annual International Congress for Fluorescence-Guided Surgery – Coral Gables, FL, 15th and 16th feb. 2020.
Home . Legal & credits
Copyright © 2023 SurgiMab. Website by B-to-B Design